From what I've read AR-V7 can be a fluid genetic variant. Some guys who are AR-V7 positive (and are Zytiga/Xtandi resistant), may become AR-V7 negative after a course of taxanes (Taxotere or Jevtana). Some guys who are AR-V7 negative become AR-V7 positive with prolonged advanced hormonal treatment. Some guys stay AR-V7 positive. Some guys stay AR-V7 negative. So my question is - how does one know whether one's AR-V7 status is permanent or subject to change? And since we don't know how to predict that, how does it benefit us to know our AR-V7 status at a given point in time?
Overriding any of this is the STAMPEDE study that proved that early use of Taxotere prolongs survival. So it seems to me that all men with adequate performance status who are diagnosed with mets should be treated with Taxotere. Taxotere works irrespective of AR-V7 status, and
may switch one's AR-V7 status to negative. Therefore,
knowing one's current AR-V7 status really doesn't help one to make a treatment decision until after Taxotere therapy
and castrate resistance.
Afterwards, if one turns out to be AR-V7 positive, one can forgo the advanced hormonals, or one can try them for a while to see if they work. If deciding on a cost basis, Zytiga costs $8,000 per month, there's whatever co-pay/deductibles one has to pay on that vs. the $1,000 out of pocket for the AR-V7 test. It seems insurance companies/Medicare would want to cover it in certain situations.
- Allen
Post Edited (Tall Allen) : 3/22/2016 4:25:53 PM (GMT-6)